Answers are grounded in this paper and cite their sources.
A new era in medicine has been made possible by recent developments in mRNA technology as well as its delivery. Since mRNA-encoded proteins don't have to plunge into the nucleus or be exposed to the possibility of integrating genetically, they are quick, powerful, and temporary, which makes them ideal for treating various types of illnesses, including cancer, contagious illnesses and monogenic disorders. The worldwide reaction to the COVID-19 pandemic was aided by the quick turnaround time and simplicity of mass-scale manufacturing of mRNA-based treatments. However, issues with mRNA stability, expression length, delivery effectiveness, and targetability all need to be resolved in order to expand the use of mRNA therapies beyond COVID-19 vaccinations. We are able to optimize the platform of mRNA to satisfy the clinical prerequisites for any illness by taking lessons from the quickly growing preclinical and clinical research. In order to create a new generation of targeted mRNA-dependent treatments, we will anticipate an overview of the latest developments in mRNA technology, including its application in vaccines, immunotherapeutic, protein replacement therapy, and genome editing as well as its distribution to particular cell types and organs.
No takes yet. Share an insight, caveat, or question.
Dwivedi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: